Distinguishing Features of Anti-β₂ Glycoprotein I Antibodies between Patients with Leprosy and the Antiphospholipid Syndrome

Summary

Anticardiolipin (ACA), anti-β2 glycoprotein I (β2GPI), and antiprothrombin antibodies of IgG and IgM classes were quantitated by enzyme-linked immunosorbent assays in 176 untreated leprosy patients across the histopathological spectrum. Positivity rates ranged from 21% (IgG ACA) to 30% (IgM anti-prothrombin) versus 4% in healthy controls (p <10-2 to 10-3). Levels of IgM anti-β2GPI and IgG ACA were significantly higher in lepromatous leprosy and multibacillary patient subgroups. IgG3 was the most common subclass reactive to both β2GPI and prothrombin in selected high-titer leprosy sera, unlike antibodies from patients with the antiphospholipid syndrome (APS) largely restricted to IgG2. In leprosy patients, but not in the APS control group, there was no statistical correlation between ACA and anti-β2GPI antibody levels. Likewise, a large fraction of anti-β2GPI positive sera (36/45 and 28/44 for IgG and IgM, respectively) were unreactive in the standard ACA assay. Most assayed anti-β2GPI antibodies from leprosy patients showed (i) ability to recognize both human and bovine β2GPI immobilized on non-irradiated polystyrene plates, (ii) concentrationdependent inhibition of binding by cardiolipin, and (iii) relatively high avidity binding to fluid-phase β2GPI, thereby differing from those found in APS. Finally, the location of the major epitopic region on the β2GPI molecule targeted by autoantibodies was different in leprosy and APS, as assessed by direct binding to domain Iand V-deleted mutants and competition with the mouse monoclonal antibody 8C3, directed at domain I. Thus, leprosy-related antiphospholipid antibodies comprise persistent IgG and IgM anti-β2GPI that differ from APS-related ones with respect to IgG subclass, avidity and epitope specificity, possibly reflecting distinct pathophysiological significance.

Keywords

Antiphospholipid syndrome - leprosy - β2 glycoprotein I - prothrombin

• References

• 1 Britton WJ. The immunology of leprosy. Trans R Soc Trop Med Hyg 1993; 46: 508-14.
• 2 Guedes LSBarbosa, Gilbrut B, Shoenfeld Y, Scheinberg MA. Autoantibodies in leprosy sera. Clin Rheumatol 1996; 15: 26-8.
• 3 Ridley D, Jopling M. Classification of leprosy according to immunity A five-group system. Int J Lepr Other Mycobact Dis 1966; 34: 255-73.
• 4 Kandiah DA, Sali A, Sheng Y, Victoria EJ, Marquis DM, Coutts SM, Krilis SA. Current insights into the “antiphospholipid” syndrome: clinical, immunological, and molecular aspects. Adv Immunol 1998; 70: 507-63.
• 5 McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-280.
• 6 Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 1999; 93: 2149-57.
• 7 Roubey RAS. Immunology of the antiphospholipid syndrome: antibodies, antigens, and autoimmune response. Thromb Haemost 1999; 82: 656-61.
• 8 Arvieux J, Pouzol P, Roussel B, Jacob MC, Colomb MG. Lupus-like anticoagulant properties of murine monoclonal antibodies to β₂-glycoprotein I. Br J Haematol 1992; 81: 568-73.
• 9 Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 1120-5.
• 10 Loizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 103-8.
• 11 Hunt JE, McNeil P, Morgan GJ, Crameri RM, Krilis SA. A phospholipid-β₂-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992; 01: 75-81.
• 12 de Larranaga GF, Forastiero RR, Martinuzzo ME, Carreras LO, Tsariktsian G, Sturno MM, Alonso BS. High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity. Lupus 2000; 09: 594-600.
• 13 Elbeialy A, Strassburger-Lorna K, Atsumi T, Bertolaccini ML, Amengual O, Hanafi M, Khamashta MA, Hughes GRV. Antiphospholipid antibodies in leprotic patients: a correlation with disease manifestations. Clin Exp Rheumatol 2000; 18: 492-4.
• 14 Fiallo P, Travaglino C, Nunzi E, Cardo PP. β₂-glycoprotein I-dependence of anticardiolipin antibodies in multibacillary leprosy patients. Lepr Rev 1998; 69: 376-81.
• 15 Hojnik M, Gilburd B, Ziporen L, Blank M, Tomer Y, Scheinberg MA, Tincani A, Rozman B, Shoenfeld Y. Anticardiolipin antibodies in infections are heterogenous in their dependency on β₂-glycoprotein I: analysis of anticardiolipin antibodies in leprosy. Lupus 1994; 03: 515-21.
• 16 Mane I, Cartel JL, Grosset JH. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results. Int J Leprosy 1997; 65: 224-9.
• 17 Wilson WA, Gharavi AE, Piette JC. International classification criteria for antiphospholipid syndrome: synopsis of a post-conference workshop held at the ninth international (Tours) aPL symposium. Lupus 2001; 10: 457-60.
• 18 Arvieux J, Regnault V, Hachulla E, Darnige L, Roussel B, Bensa JC. Heterogeneity and immunochemical properties of anti-β₂-glycoprotein I autoantibodies. Thromb Haemost 1998; 80: 393-8.
• 19 Sheng Y, Kandiah DA, Krilis SA. Anti-β₂-glycoprotein I autoantibodies from patients with the “antiphospholipid” syndrome bind to β₂-glycoprotein I with low affinity: dimerization of β₂-glycoprotein I induces a significant increase in anti-β₂-glycoprotein I antibody affinity. J Immunol 1998; 161: 2038-43.
• 20 Arvieux J, Roussel B, Ponard D, Colomb MG. IgG₂ subclass restriction of anti-β₂ glycoprotein I antibodies in autoimmune patients. Clin Exp Immunol 1994; 95: 310-5.
• 21 Bouma B, de Groot PG, van den Elsen JMH, Ravelli RBG, Schouten A, Simmelink MJA, Derksen RHWM, Kroon J, Gros P. Adhesion mechanism of human β₂-glycoprotein I to phospholipids based on its crystal structure. Embo J 1999; 18: 5166-74.
• 22 Panunto-Castelo A, Almeida IC, Rosa JC, Greene LJ, Roque-Barreira MC. The Rubino test for leprosy is a β₂-glycoprotein I-dependent antiphospholipid reaction. Immunology 2000; 101: 147-53.
• 23 Arvieux J, Darnige L, Hachulla E, Roussel B, Bensa JC, Colomb MG. Species specificity of anti-β₂-glycoprotein I autoantibodies and its relevance to anticardiolipin antibody quantitation. Thromb Haemost 1996; 75: 725-30.
• 24 Santiago M, Martinelli R, Ko A, Reis EA, Fontes RD, Nascimento EG, Pierangeli S, Espinola R, Gharavi A. Anti-β₂ glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kala-azar. Clin Exp Rheumatol 2001; 19: 425-30.
• 25 Iverson GM, Victoria EJ, Marquis DM. Anti-β₂ glycoprotein I (β₂GPI) autoantibodies recognize an epitope on the first domain of β₂GPI. Proc Natl Acad Sci USA 1998; 95: 15542-6.
• 26 Reddel SW, Wang YX, Sheng YH, Krilis SA. Epitope studies with anti-β₂GPI-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmunity 2000; 15: 91-6.
• 27 McNeeley PA, Dlott JS, Furie RA, Jack RM, Ortel TL, Triplett DA, Victoria EJ, Linnik MD. β₂-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of β₂-glycoprotein I. Thromb Haemost 2001; 86: 590-5.
• 28 George J, Gilburd B, Hojnik M, Levy Y, Langevitz P, Matsuura E, Koike T, Shoenfeld Y. Target recognition of β₂-glycoprotein I (β₂GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of β₂GPI in antibody binding. J Immunol 1998; 160: 3917-23.
• 29 Bakos L, Correa CC, Bergmann L, Bonamigo RR, Muller LF. Antiphospholipid antibodies thrombotic syndrome misdiagnosed as Lucio’s phenomenon. Int J Lepr Other Mycobact Dis 1996; 64: 320-3.
• 30 Hussain R, Kifayet A, Chiang TJ. Immunoglobulin G₁ (IgG₁) IgG₃ antibodies are markers of progressive disease in leprosy. Infect Immun 1995; 63: 410-5.